Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.59 |
| ▸ | QSOX1 | O00391 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248745 | 0.96 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3QSOX1 | |
| SCHEMBL6248740 | 0.96 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3QSOX1 | |
| SCHEMBL6248737 | 0.96 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3QSOX1 | |
| SCHEMBL6250983 | 0.90 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3QSOX1 | |
| SCHEMBL6250976 | 0.90 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3QSOX1 | |
| SCHEMBL6250980 | 0.90 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3QSOX1 | |
| SCHEMBL6247848 | 0.89 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3QSOX1 | |
| SCHEMBL6247849 | 0.89 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3QSOX1 | |
| SCHEMBL6247852 | 0.89 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3QSOX1 | |
| SCHEMBL3363477 | 0.88 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3QSOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279990-A1 | ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2010-11-04 | — | — | US | disclosed |
| US-20100130549-A1 | PSYCHOTROPIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2010-05-27 | — | — | US | disclosed |
| EP-2029517-A2 | ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Ramot at Tel-Aviv University Ltd. (IL) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146796-A2 | ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279990-A1 | ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | STRA6, GPR6, CCNO | SLC6A4 326/4885SLC6A2 102/4885SLC6A3 118/4885 |
| US-20100130549-A1 | PSYCHOTROPIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SLC6A2, CHRNA6, SLC6A3 | SLC6A4 7/4885SLC6A2 1/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.